Enterprise Value
483.3M
Cash
350.4M
Avg Qtr Burn
-8.365M
Short % of Float
9.29%
Insider Ownership
7.45%
Institutional Own.
38.53%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lupkynis (Voclosporin) Details Lupus nephritis | Approved Quarterly sales | |
Voclosporin Ophthalmic Solution Details Dry eye syndrome | Failed Discontinued | |
Voclosporin Details Focal segmental glomerulosclerosis | Failed Discontinued |